Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Semaglutide cut heavy drinking in AUD trial
The SEMALCO trial found semaglutide reduced heavy drinking days by 41 percentage points versus 26 on placebo in adults with AUD and obesity.
Semaglutide in children: Iceland cohort
Iceland's 2026 nationwide cohort found subsidised semaglutide reversed BMI in children with grade 2 obesity; 63% hit clinically meaningful reductions.
How semaglutide is measured in plasma
A 2026 HPLC-MS/MS assay measures semaglutide in plasma at 5-200 ng/mL. Why validated bioanalytical methods matter for pharmacokinetics and product quality.
Tesamorelin and visceral fat: the evidence
FDA-approved for HIV lipodystrophy only. What the trial evidence covers, what it does not, and what to ask a clinician.
BPC-157 and TB-500: Achilles tendon healing
A 2026 rat study tested BPC-157 and TB-500 after Achilles repair. TB-500 improved tensile strength and collagen scores; combining both added no extra benefit.
BPC-157 for UC and MS: the evidence
Rodent models show gut-repair effects, but no human trial has published results for UC or MS. Interaction data with azathioprine or teriflunomide is absent.
Rat Achilles study: BPC-157 and TB-500
A 32-rat Achilles repair study found TB-500 improved load to failure and tendon histology at four weeks. BPC-157 did not reach significance.
The first week on ipamorelin and CJC-1295
Two good nights on an ipamorelin and CJC-1295 blend is not a result yet. Here is what the published timelines actually look like.
Ipamorelin + CJC-1295: early effects
Community reports of better sleep within days of starting ipamorelin and CJC-1295 align with GH-axis pharmacology. Here is what the published literature says.
Peptide blood tests before and after
What a before and after blood panel can show around retatrutide, hCG or Semax, what it cannot, and why interpretation belongs with a clinician.
Why you cannot tell which peptide did it
Running BPC-157, TB-500 and tirzepatide together makes every result uninterpretable. Here is why pharmacology treats one variable at a time.
Peptide stacking: the attribution problem
Running six research peptides at once creates an attribution problem you cannot solve. Here is what the evidence says about polypharmacy risk and safety gaps.